The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Optimal management of Hodgkin lymphoma in elderly patients and those with comorbidities
Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MN, outlines the optimal treatment strategies for Hodgkin lymphoma in elderly patients and in those with comorbidities. Prof. Ansell explains that novel agents like the antibody-drug conjugate brentuximab vedotin, as well as PD-1 blockade, have demonstrated high response rates; however, this has been shown to be at the expense of the durability of these responses. One strategy that has shown promising results has been the use of novel agents like brentuximab vedotin pre- and post-chemotherapy. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Stephen Ansell, MD, PhD, has received institutional research funding for clinical trials from Bristol Myers Squibb, Takeda, SeaGen, Regeneron, Trillium and ADC Therapeutics.
